Ras: PPI inhibitors for the treatment of cancer

Identification of inhibitors of RAS-effector protein interaction using a fragment-based drug design approach

Domainex employed a number of techniques and its extensive experience of fragment-based drug design to develop fragment hits which exhibited  RAS binding. These fragment hits were developed into leads with increased binding affinity and improved physical properties.

Oxford University Logo


Activating RAS mutations are associated with approximately 30% of cancers; therefore, blocking RAS-effector interactions with biological reagents has beneficial effects in cancer models. Professor Terry Rabbitts of the University of Oxford, commissioned Domainex to help develop fragment hits into lead molecules, which bind potently to activated RAS and inhibit binding of effector proteins such as PI3K and Raf. This work was unprecedented when it was initiated.

RAS Figure 1
Figure 1: RAS-effector interactions


Prior to Domainex starting work on the programme, a fragment hit (Abd-1) that demonstrated selective binding to GTP-bound RAS (i.e. the active form) was identified from an SPR screen of a fragment library of 656 compounds.

RAS Figure 2
Figure 2: Abd-1 was identified from an SPR screen. Top panel: Abd-1 with HRASG12V-GTPɣS. Lower panel: Abd-1 with HRASG12V-GDP.

The SAR around Abd-1 was explored to generate Abd-2, which had increased RAS-binding affinity and improved aqueous solubility. These superior properties facilitated structural biology studies and enabled the binding mode to be confirmed by X-ray crystallography.

Figure 3: Abd-2 was developed which had increased RAS-binding affinity and aqueous solubility
Figure 3: Abd-2 was developed which had increased RAS-binding affinity and aqueous solubility
RAS Figure 4
Figure 4: A crystal structure of Abd-2 confirmed the binding mode

Domainex medicinal chemists then commenced work on the programme. We utilised our experience in fragment-based drug discovery and were able to develop the fragment hits into lead molecules using a structure-guided approach. RAS-binding was enhanced, and a solubilising substituent was introduced to enhance the physical properties in order to assist with the X-ray crystallography.

RAS Figure 5
Figure 5: Residues binding to effector proteins highlighted in yellow

Small H-bonding groups proved to be ineffective in forming additional interactions with RAS, but an 8-pyridyl substituent showed a significant improvement in potency. X-ray crystallography showed that this induced a conformational change (see Figure 6):

  • Asp-54 rotation opens up a lipophilic feature to accommodate aromatic group
  • Arg-41 moves closer to pocket

RAS Figure 6a RAS Figure 6b

Figure 6: 8-Pyridyl substitution induced a conformational change

The conformational change presented an opportunity for growth towards the Switch 1 region, accessible via substitution on the pyridyl ring, which led to increased binding affinity.

RAS Figure 7
Figure 7: Crystal structure of a novel inhibitor of RAS-effector protein interactions bound to KRAS (from pdb 6FA4) compared with original fragment hit (Abd-2) (fine grey lines)

Finally, removal of the solubilising group increased ligand efficiency, resulting in the cell-permeable RAS PPI inhibitor, Abd-7. The Rabbitts group showed that Abd-7 disrupted the interaction of RAS with a range of effector proteins, and modulated signalling downstream of RAS, eliciting a reduction in phosphorylation of downstream proteins AKT and ERK.1

RAS Figure 8
Figure 8: Lead molecule bound to RAS


Domainex utilised its extensive experience of fragment- and structure-based drug design to elaborate a fragment hit into a lead molecule with efficient binding to RAS. This and related compounds were shown to inhibit the protein-protein interactions between RAS and effector proteins and tumour viability in cellular assays.

Domainex Expertise

Medicinal and Synthetic ChemistryFragment-based Drug Design (FBDD)Structure-based Drug Design (SBDD)

DMPK and ADME • Lead OptimisationProtein-protein Interaction Drug DiscoveryOncology


1. Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment. Camilo E. Quevedo, Abimael Cruz-Migoni, Nicolas Bery, Ami Miller, Tomoyuki Tanaka, Donna Petch, Carole J.R. Bataille, Lydia Y.W. LeePhillip S. Fallon, Hanna Tulmin, Matthias T. Ehebauer, Narcis Fernandez-Fuentes, Angela J. Russell, Stephen B. Carr, Simon E.V. Phillips and Terence H. Rabbitts., Nat Commun 9, 3169 (2018).

Press release

A new class of RAS-effector protein-protein interaction inhibitors
20th December 2018